- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02524054
Aerosol Inhalation Treatment for Dyspnea - Patients
Aerosol Inhalation Treatment for Dyspnea
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is the second study in a series of studies investigating the treatment effect of aerosolized furosemide on hospitalized patients and outpatients with intractable dyspnea. The study will focus on patients who experience intractable dyspnea at rest or with minimal activity, e.g., dressing, bathing, cooking, or walking stairs or short distances.
There are two parts to this study: Study 2a is a pilot study on 5-10 patients. These trials are not blinded or placebo controlled; the investigators will use them to discover practical problems, and take the information back to the laboratory to develop solutions. We enrolled 7 subjects for Study 2a.
Study 2b will a randomized, placebo - controlled, double- blind study on 25 - 40 patients. The two planned treatments will be aerosolized furosemide and aerosolized saline, and will be given to each patient on two separate days. We failed to reach our enrollment goal, and ultimately enrolled 17 subjects for participation in Study 2b.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Intractable dyspnea at rest or with minimal activity
Exclusion Criteria:
- Chronic congestive heart failure
- Liver or kidney disease
- Systemic lupus erythematosis (SLE)
- Receiving potassium supplementation or other indication of hypokalemia
- Major psychiatric disorders
- Furosemide hypersensitivity
- Not mentally competent and/or alert (unable to grant informed consent)
- Under 18 years old
- Not fluent in English
- Inadequate birth control
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aerosol furosemide Study 2a
Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min.
This will be a single, unblinded administration.
|
80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers.
Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Other Names:
|
Experimental: Aerosol furosemide Study 2b Arm F
Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day.
Baseline measurement 15 min; Inhalation over the course of 10-15 min.;
outcome measurement 15 min.
Watch for adverse effects 2 hours.
|
80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers.
Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Other Names:
8ml saline will be aerosolized using ultrasonic screen nebulizers.
Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Other Names:
|
Experimental: Aerosol furosemide Study 2b Arm S
Inhalation of saline aerosol one one day then furosemide aerosol on another day.
Baseline measurement 15 min; Inhalation over the course of 10-15 min.;
outcome measurement 15 min.
Watch for adverse effects 2 hours.
|
80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers.
Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Other Names:
8ml saline will be aerosolized using ultrasonic screen nebulizers.
Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Subject Rating of Breathing Discomfort (Dyspnea) Before and After Treatment.
Time Frame: 15 min
|
Subjects will rate breathing discomfort (dyspnea) during a 15 min exercise test using a visual analog scale before and after drug (or placebo) intervention. The treatment effect was measured as the rating of breathing discomfort rating before treatment minus the rating of breathing discomfort after treatment at equivalent work intensities. Outcome Measure Time Frame: subjects performed arm exercise to induce dyspnea for approximately 15 min before and after aerosol inhalation. the average number of minutes between end of drug administration and post-intervention breathing discomfort rating: Aerosol furosemide Study 2a arm: 38.7 minutes; Aerosol furosemide Study 2b arm: 21.8 minutes; Aerosol saline Study 2b arm: 21.3 minutes |
15 min
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine Output - mL
Time Frame: Summation of total urine output (mL) at 1 hour following drug administration.
|
Diuresis is an expected effect of furosemide. To the extent that aerosol furosemide is absorbed in the blood, diuresis is an expected 'side effect' of this treatment. Following intervention, study team will measure urine output (mL). Study team will then rehydrate subject with an equal amount of liquid to their output. |
Summation of total urine output (mL) at 1 hour following drug administration.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert Banzett, PhD, Beth Israel Deaconess Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011P000027
- R01NR012009 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspnea
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea Invasive Mechanical Ventilation-associatedFrance
-
Mayo ClinicCompletedShortness of Breath | Cardiac; DyspneaUnited States
-
Qure Healthcare, LLCJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedDyspnea | Unexplained Chronic DyspneaUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedRelationship Between Dyspnea and Ventilatory VariabilityFrance
-
University of MonastirCompleted
-
University of California, Los AngelesNot yet recruitingShortness of Breath/Dyspnea
-
Medical University of ViennaRecruitingEchocardiography | Acute DyspneaAustria
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea and Respiratory Insufficiency in ChildrenFrance
-
Intersection Medical, Inc.CompletedPulmonary Congestion | Dyspnea, | Acute Heart Failure SyndromeUnited States
-
University of MonastirCompletedDyspnea; CardiacTunisia
Clinical Trials on Furosemide
-
NYU Langone HealthWithdrawnPremature Birth | Premature InfantUnited States
-
Johns Hopkins UniversityscPharmaceuticals, Inc.Completed
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States, Canada
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedBronchopulmonary DysplasiaUnited States
-
Jan Kochanowski UniversityRecruiting
-
Chiang Mai UniversityRecruiting
-
Stadtspital ZürichOspedale Regionale di LuganoRecruitingAcute Heart Failure | Diuretic ResistanceSwitzerland
-
Puerta de Hierro University HospitalInstituto de Salud Carlos III; Spanish Society of CardiologyCompleted